Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015
  • USA - English


News provided by

Genelex

Jun 03, 2015, 10:05 ET

Share this article

Share toX

Share this article

Share toX

Medicare health insurance benefits for drug sensitivity testing changes on June 22
Medicare health insurance benefits for drug sensitivity testing changes on June 22

Seattle, WA (PRWEB) June 03, 2015 -- On June 22, 2015, Medicare will begin denying coverage for the majority of genetic drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009.

Payment denial is expected to impact as many as 19 million of the 49 million Medicare beneficiaries in the U.S. who are at special risk of costly and life-threatening adverse drug events.(1) Sadly, if it became a standard of care, this testing could save Medicare millions.

Denying payment for these medically necessary tests is counter to the Triple Aim. Use of these tests could help doctors avoid unnecessary treatment failures and dangerous side effects," says Kristine Ashcraft, COO at Genelex

Post this

Precision Medicine, the use of an individual’s genetic information to tailor treatment, is by all accounts the future of healthcare. Despite the large body of clinical research supporting the utility of this testing – 17,000 pieces of clinical literature and counting – Medicare’s judgement that there is insufficient evidence to demonstrate that genetic testing improves clinical outcomes could set back adoption of this life-saving test by years.

What is Pharmacogenetic Testing?
Pharmacogenetic (PGx) testing reveals genetic variations that determine how the body metabolizes many of the most commonly prescribed medications. The testing reduces “trial-and-error” prescribing by enabling doctors to prescribe the most effective drug and dose the first time, potentially reducing side effects while saving both the patient and the healthcare system as a whole time and money.

Why is Pharmacogenetic Testing Important?
Research has shown that three out of four people have a genetic variation affecting their response to drugs. Genetically determined variation in drug response is so common that the FDA has included information about drug-gene interactions on more than 130 medication product inserts.

The potential cost-savings of widespread pharmacogenetic testing is huge. According to the CDC, adverse drug events cost the U.S. health system approximately $3.5 billion annually.(2) More than a third of potential clinically significant drug interactions, a potential cause of adverse drug events, have been shown to involve genetics.(3) Recent analysis of the recently released CMS Medicare Part D prescription drug data from 2013 suggests:

• $1.5 billion and 38,000 lives -- that’s what genetic testing could potentially save for acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI), who are on the heart medications clopidogrel (Plavix), prasugrel, and ticragelor. In total, 2.9 million Medicare recipients were on at least one of these medications. Medicare spent $894 million on these drugs combined, with Plavix/clopidogrel costs representing 80 percent of that figure.(4)
• Between 560,000 and 1.1 million Medicare recipients could be experiencing ineffective pain relief due to genetic variability while taking hydrocodone-acetaminophen, the prescription painkiller taken by the highest number of Medicare patients. In 2013, Medicare spent roughly $567 million on this drug for 8 million individual beneficiaries (about $70 per person). This is even more alarming considering untreated pain is a leading cause for falls, leading to hospitalization in the elderly.

Impact on the Elderly

Statistics show that adverse drug reactions, a specific subset of adverse drug events, cause 1 in 8 hospitalizations, with the elderly being twice as likely to be hospitalized by an adverse drug reaction compared to the non-elderly.(5,6) Though it’s unclear how many of these are caused by drug-gene interactions, many Medicare patients are at particularly high risk, since 44 percent of men and 57 percent of women over 65 take five or more medications per week.(7) Additionally, the metabolism of six of the top 10 drugs by Medicare claim count is potentially affected by genetics.

“Pharmacogenetic testing has been a covered benefit since 2009. Denying payment for these medically necessary tests is counter to the Triple Aim. Use of these tests could help doctors avoid unnecessary treatment failures and dangerous side effects; plus could reduce the more than $2000 per patient per year Medicare spends on adverse drug events,” said Kristine Ashcraft, Chief Operating Officer at Genelex. “This testing is the underpinning of precision medicine that President Obama recently called out as a national priority, and is required for better patient care.”

The potential for improvements in patient care and costs are not lost on physicians, whose use of PGx testing continues to be on the rise. A 2012 survey published in Clinical Pharmacology and Therapeutics reports that 12 percent of physicians have ordered PGx testing in the last six months, and 26 percent anticipate ordering a test in the next six months.(8) A survey completed in 2014, published in the journal Pharmacogenomics and Personalized Medicine, found that 20 percent of surveyed physicians had ordered a PGx test in the last year.(9)

Drug sensitivity tests remain available after June 22 from Genelex and other laboratories. Medicare patients talking multiple medications, experiencing treatment failures or unwanted side effects are encouraged to request this testing before the cut-off date (the public is encouraged to visit this patient information site: http://genelex.com/seniors). See links below for further information about Medicare and pharmacogenetic testing.

# # #

About Genelex
Genelex is a pioneer in comprehensive medication management, pharmacogenetic testing and analysis. Its patented YouScript® Personalized Prescribing Software is the only commercially-available medication management system to assess the cumulative effect of a patient’s genetics and entire drug regimen. YouScript is an Allscripts Developer Program Approved Application and is used by healthcare providers, clinical researchers and managed and accountable care organizations. Founded in 1987, Genelex is based in Seattle and was one of the first labs to provide pharmacogenetic testing and interpretation. For more information, please go to: http://www.genelex.com or http://www.youscript.com.

Editor Contact:
Jodie Cadieux
Director of Marketing and Product Management
O: 206.826.1930
Email: Jodie(at)genelex(dot)com

Or:

Bob Reed
For Genelex
P: 630.579.1770
Bob(at)rurelevant(dot)com

For immediate further information about drug-gene testing:

Noridian Medicare Administrative Contractor Final Coverage Decision

Medicare statement, May 8, 2015

Medicare beneficiaries by state: http://kff.org/medicare/state-indicator/total-medicare-beneficiaries/

American Medical Association information about pharmacogenetics:
http://www.ama-assn.org/ama/pub/physician-resources/medical-science/genetics-molecular-medicine/current-topics/pharmacogenomics.page

Medical studies and citations: The Case for Pharmacogenetics: http://genelex.com/wp-content/uploads/2015/05/2015-05-25_-The-Case-for-Pharmacogenetic-Testing-Fact-Sheet-FINAL.pdf

Drug sensitivity testing Information for patients: http://genelex.com/patients/

Genelex Media Kit: http://www.genelex.com/media

SOURCES:

1. Based on current figures from the Kaiser Foundation in a recent study about the incidence of high-risk medications in patients 65 and over, and phenotype frequency data.

2. http://www.cdc.gov/medicationsafety/basics.html

3. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655-65. Epub 2014/05/07. doi: 10.2217/pgs.14.6. PubMed PMID: 24798722.4. Figures are based on an economic model created to show the possible positive impact of pharmacogenetic testing on ACS/PCI patients, using recently released CMS Medicare Part D prescription drug data that detailed how many Medicare patients were prescribed clopidogrel (also known as Plavix), prasugrel, and ticragelor in 2013.

5. Jansen PA, Brouwers JR. Clinical pharmacology in old persons. Scientifica. 2012;2012:723678. PubMed PMID: 24278735

6. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy world & science : PWS. 2002;24(2):46-54.
PubMed PMID: 12061133.

7. Woodruff B. Preventing polypharmacy in older adults. American Nursing Today. 2010; 5(10). Available from: http://www.americannursetoday.com/preventing-polypharmacy-in-older-adults/

8. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450-8. PubMed PMID: 22278335.

9. Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 2014;7:145-62. PubMed PMID: 25045280.

Jodie Cadieux, Genelex, http://genelex.com, +1 206.229.8521, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.